Needham Reiterates Buy on Taysha Gene Therapies, Maintains $10 Price Target

Taysha Gene Therapies, Inc. -2.60%

Taysha Gene Therapies, Inc.

TSHA

4.49

-2.60%

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ: TSHA) with a Buy and maintains $10 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via